Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 06, 2018 08:00 ET | Source: Mapi Pharma Ltd.

Mapi Pharma to Host Key Opinion Leader Meeting on Long Acting Glatiramer Acetate (GA Depot) for Multiple Sclerosis

NESS ZIONA, Israel, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, clinical late stage biopharmaceutical company, announced today that it will host a Key Opinion Leader...
January 30, 2018 08:00 ET | Source: Mapi Pharma Ltd.

First Patient Treated in Mapi Pharma’s Phase II Clinical Trial of GA Depot for Primary Progressive Multiple Sclerosis (PPMS)

Study is being conducted on strength of prior Phase II clinical trial that showed strong efficacy in RRMS patients who switched from Copaxone® to once-monthly GA Depot NESS ZIONA, Israel, Jan. 30,...
October 31, 2017 06:30 ET | Source: Mapi-Pharma Ltd.

Mapi Pharma Announces Presentation of Phase II Results of Glatiramer Acetate Depot at ECTRIMS-ACTRIMS 2017 Congress in Paris

Data Suggest that GA Depot Has Potential to Ease the Treatment Burden and Improve Patient Compliance in MS Patients on GA Depot Achieved a No Evidence of Disease Activity (NEDA) Score of 84.6% Phase...
August 17, 2017 08:00 ET | Source: Mapi-Pharma Ltd.

Mapi Pharma Ltd. Announces Closing of $10 Million Investment

NESS ZIONA, Israel, Aug. 17, 2017 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a privately held, fully integrated, clinical stage biopharmaceutical company has completed an investment round of $10 million...